News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

PledPharma awarded Nordic Star of the Year

September 10, 2014

PledPharma AB
Company Announcement

PledPharma awarded Nordic Star of the Year

Stockholm, 2014-09-10 08:00 CEST (GLOBE NEWSWIRE) -- 
PledPharma, the Swedish pharmaceutical company that develops new therapies for
life threatening diseases, has been acknowledged Nordic Star of the Year at the
Nordic Life Science Days Conference held in Stockholm, Sweden, during September
8-9, 2014. PledPharma is the Swedish representative among the three companies
that showcase the strong innovation of the Nordic Life Science industry. 

During this year’s edition of Nordic Life Science Days, PledPharma was rewarded
for being a shining example of an innovative life science company. 

“PledPharma has an exciting clinical project platform that is based on a novel
technology and targets significant medical needs. Step by step are they
confidently moving towards their goal. Expect no less from a Nordic Star! ” 

About Nordic Stars Awards

The Nordic Stars Awards was established in 2013 to reward companies that
highlight the innovative Nordic life science community. 

Nordic Life Science Days

Nordic Life Science Days is the Nordic region’s largest partnering conference
for the global life science industry. The conference attracts leading
decision-makers in the life science sector, including the bioengineering,
pharmaceuticals and Med Tech segments, along with investors, research
institutions, politicians and authorities. This year’s Nordic Life Science Days
event is taking place in partnership with Oslo Cancer Cluster and Toulouse
Cancer-Bio-Santé Cluster. 

For further information, please contact:

Jacques Näsström, CEO

+46 737 13 09 79

Michaela Gertz, CFO

+46 709 26 17 75

About PledPharma

PledPharma is a Swedish pharmaceutical company that develops new therapies for
the treatment of life threatening diseases. The initial objective is to develop
a drug, PledOx®, which reduces severe side-effects associated with
chemotherapy. The current market for supportive cancer care is some USD 10
billion. PledPharma also evaluates an existing medicines possibility to reduce
the damage that occurs on the heart muscle when patients suffer from acute
myocardial infarction. In addition to these projects, the company is also
evaluating opportunities of using our technology platform in additional areas
where there is a significant unmet medical need. PledPharma has the potential
to offer patients valuable and unique treatments for serious life-threatening
diseases where there is an opportunity fast registration in the US through
"breakthrough therapy" designation. This means that the company has the
potential to offer shareholders a good return on their investment. PledPharma
(STO:PLED) is listed on NASDAQ OMX First North. Erik Penser Bankaktiebolag is
the Certified Adviser. For further information, please visit



Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10